Also i think its interesting to take a step back and look at...

Also i think its interesting to take a step back and look at these results. Median progression free survival is 8.4 (6.6-10.2) compared to historical median 5.3. That means that not one of the patients in the cohort had a pfs as low as the median for the historical data. That is quite something. The increasingly good data and the drugs low toxicity profile will see it combined in multiple other combination trials this coming year. Mark my words.